维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

2篇 您的检索式：作者名="Gu Mengnan"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Procalcitonin could be a reliable marker in differential diagnosis of post-implantation syndrome and infection after percutaneous endovascular aortic repair显示文摘	Xue Ling Luo Songyuan Luo Jianfang Liu Zhen Gu Mengnan Kang Huiyuan Yang Fan Nie Bingrong Liu Yuan Huang Wenhui Xie Nianjin He Pengcheng Dong Haojian Ni Zhonghan Fan Ruixin Chen Jiyan	2014	Chinese Medical Journal2014，，14：	8
	2	A novel humanized MUC1 antibody–drug conjugate for the treatment of trastuzumab-resistant breast cancer显示文摘Mucin 1(MUC1)has been regarded as an ideal target for cancer treatment,since it is overexpressed in a variety of different cancers including the majority of breast cancer.However,there are still no approved monoclonal antibody drugs targeting MUC1.In this study,we generated a humanized MUC1(HzMUC1)antibody from our previously developed MUC1 mouse monoclonal antibody that only recognizes MUC1 on the surface of tumor cells.Furthermore,an antibody–drug conjugate(ADC)was generated by conjugating HzMUC1 with monomethyl auristatin(MMAE),&the efficacy of HzMUC1-MMAE on the MUC1-positive HER2+breast cancer in vitro&in‘Xenograft’model was tested.Results from western blot analysis&immunoprecipitation revealed that the HzMUC1 antibody did not recognize cell-free MUC1-N in sera from breast cancer patients.Confocal microscopy analysis showed that HzMUC1 antibody bound to MUC1 on the surface of breast cancer cells.Results from mapping experiments suggested that HzMUC1 may recognize an epitope present in the interaction region between MUC1-N and MUC1-C.Results from colony formation assay&flow cytometry demonstrated that HzMUC1-MMAE significantly inhibited cell growth by inducing G2/M cell cycle arrest&apoptosis in trastuzumab-resistant HER2-positive breast cancer cells.Meanwhile,HzMUC1-MMAE significantly reduced the growth of HCC1954 xenograft tumors by inhibiting cell proliferation&enhancing cell death.In conclusion,our results indicate that HzMUC1-ADC is a novel therapeutic drug that can overcome trastuzumab resistance of breast cancer.HzMUC1-ADC should also be an effective therapeutic drug for the treatment of different MUC1-positive cancers in clinic.	Guang Wu Lan Li Yuxin Qiu Wei Sun Tianhao Ren Yingshuai Lv Mengnan Liu Xiaoxia Wang Hongqun Tao Lingjie Zhao Jiawei Cao Licai He Hongzhi Li Haihua Gu	2021	Acta Biochimica et Biophysica Sinica2021，53，12：	2

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费